Precipio, Inc. (PRPO)
USD 5.56
(-3.81%)
USD 5.56
(-3.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.85 Million USD | 52.04% |
| 2022 | -12.2 Million USD | -42.73% |
| 2021 | -8.55 Million USD | 30.09% |
| 2020 | -12.23 Million USD | 7.65% |
| 2019 | -13.24 Million USD | 15.62% |
| 2018 | -15.69 Million USD | 24.16% |
| 2017 | -20.69 Million USD | -171.72% |
| 2016 | -7.61 Million USD | 76.89% |
| 2015 | -32.95 Million USD | -136.36% |
| 2014 | -13.94 Million USD | 12.79% |
| 2013 | -15.98 Million USD | -91.99% |
| 2012 | -8.32 Million USD | 14.87% |
| 2011 | -9.78 Million USD | -212.13% |
| 2010 | -3.13 Million USD | -63.23% |
| 2009 | -1.92 Million USD | -287.88% |
| 2008 | -495 Thousand USD | 76.51% |
| 2007 | -2.1 Million USD | 38.59% |
| 2006 | -3.43 Million USD | 77.12% |
| 2005 | -14.99 Million USD | 56.38% |
| 2004 | -34.37 Million USD | -49.72% |
| 2003 | -22.95 Million USD | -7.46% |
| 2002 | -21.36 Million USD | -188.68% |
| 2001 | -7.4 Million USD | 14.55% |
| 2000 | -8.66 Million USD | 11.86% |
| 1999 | -9.82 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.22 Million USD | 41.32% |
| 2024 Q1 | -2.07 Million USD | -324.76% |
| 2023 Q1 | -3.03 Million USD | -31.63% |
| 2023 FY | -5.85 Million USD | 52.04% |
| 2023 Q4 | 925 Thousand USD | 163.57% |
| 2023 Q3 | -1.45 Million USD | 36.55% |
| 2023 Q2 | -2.29 Million USD | 24.52% |
| 2022 Q2 | -1.84 Million USD | 57.64% |
| 2022 FY | -12.2 Million USD | -42.73% |
| 2022 Q3 | -3.12 Million USD | -68.9% |
| 2022 Q4 | -2.3 Million USD | 26.1% |
| 2022 Q1 | -4.36 Million USD | -97.96% |
| 2021 FY | -8.55 Million USD | 30.09% |
| 2021 Q2 | -3.01 Million USD | -107.51% |
| 2021 Q3 | -1.86 Million USD | 38.27% |
| 2021 Q4 | -2.2 Million USD | -18.55% |
| 2021 Q1 | -1.45 Million USD | 22.31% |
| 2020 Q2 | -2.24 Million USD | 29.83% |
| 2020 FY | -12.23 Million USD | 7.65% |
| 2020 Q3 | -3.3 Million USD | -46.82% |
| 2020 Q4 | -1.86 Million USD | 43.4% |
| 2020 Q1 | -3.2 Million USD | 15.23% |
| 2019 FY | -13.24 Million USD | 15.62% |
| 2019 Q1 | -1.65 Million USD | 74.87% |
| 2019 Q2 | -5.91 Million USD | -257.93% |
| 2019 Q3 | -1.89 Million USD | 67.92% |
| 2019 Q4 | -3.78 Million USD | -99.31% |
| 2018 Q1 | -2.43 Million USD | 75.55% |
| 2018 FY | -15.69 Million USD | 24.16% |
| 2018 Q4 | -6.57 Million USD | -70.82% |
| 2018 Q3 | -3.84 Million USD | -35.96% |
| 2018 Q2 | -2.83 Million USD | -16.07% |
| 2017 FY | -20.69 Million USD | -171.72% |
| 2017 Q1 | -1.76 Million USD | -23.3% |
| 2017 Q2 | -3.68 Million USD | -108.85% |
| 2017 Q4 | -9.97 Million USD | -58.84% |
| 2017 Q3 | -6.28 Million USD | -70.65% |
| 2016 Q2 | -997 Thousand USD | 69.45% |
| 2016 Q4 | -1.42 Million USD | 25.8% |
| 2016 FY | -7.61 Million USD | 76.89% |
| 2016 Q1 | -3.26 Million USD | 83.12% |
| 2016 Q3 | -1.92 Million USD | -93.18% |
| 2015 Q3 | -7.29 Million USD | -122.87% |
| 2015 FY | -32.95 Million USD | -136.36% |
| 2015 Q2 | -3.27 Million USD | -7.69% |
| 2015 Q1 | -3.04 Million USD | 47.51% |
| 2015 Q4 | -19.33 Million USD | -164.95% |
| 2014 Q2 | -3.89 Million USD | 6.78% |
| 2014 FY | -13.94 Million USD | 12.79% |
| 2014 Q1 | -4.17 Million USD | -4.87% |
| 2014 Q4 | -5.79 Million USD | -7141.25% |
| 2014 Q3 | -80 Thousand USD | 97.95% |
| 2013 FY | -15.98 Million USD | -91.99% |
| 2013 Q4 | -3.98 Million USD | 28.28% |
| 2013 Q2 | -2.86 Million USD | 20.05% |
| 2013 Q3 | -5.55 Million USD | -93.65% |
| 2013 Q1 | -3.58 Million USD | -55.04% |
| 2012 Q3 | -2.75 Million USD | -389.17% |
| 2012 Q4 | -2.31 Million USD | 16.01% |
| 2012 Q2 | -563 Thousand USD | 79.12% |
| 2012 Q1 | -2.69 Million USD | -1125.1% |
| 2012 FY | -8.32 Million USD | 14.87% |
| 2011 Q4 | 263 Thousand USD | 120.71% |
| 2011 Q3 | -1.27 Million USD | 78.83% |
| 2011 Q2 | -5.99 Million USD | -115.91% |
| 2011 Q1 | -2.77 Million USD | -262.19% |
| 2011 FY | -9.78 Million USD | -212.13% |
| 2010 Q3 | -898 Thousand USD | 21.64% |
| 2010 Q4 | -767 Thousand USD | 14.59% |
| 2010 Q2 | -1.14 Million USD | -253.7% |
| 2010 FY | -3.13 Million USD | -63.23% |
| 2010 Q1 | -324 Thousand USD | -351.16% |
| 2009 FY | -1.92 Million USD | -287.88% |
| 2009 Q1 | -953 Thousand USD | -335.16% |
| 2009 Q4 | 129 Thousand USD | 135.25% |
| 2009 Q3 | -366 Thousand USD | 49.86% |
| 2009 Q2 | -730 Thousand USD | 23.4% |
| 2008 Q2 | 101 Thousand USD | -17.21% |
| 2008 Q1 | 122 Thousand USD | -42.45% |
| 2008 Q3 | -499 Thousand USD | -594.06% |
| 2008 Q4 | -219 Thousand USD | 56.11% |
| 2008 FY | -495 Thousand USD | 76.51% |
| 2007 Q3 | -1.34 Million USD | -696.9% |
| 2007 Q1 | -1.19 Million USD | -14.89% |
| 2007 FY | -2.1 Million USD | 38.59% |
| 2007 Q4 | 212 Thousand USD | 115.72% |
| 2007 Q2 | 226 Thousand USD | 118.9% |
| 2006 Q4 | -1.04 Million USD | 38.37% |
| 2006 Q2 | -383 Thousand USD | -20.44% |
| 2006 Q3 | -1.68 Million USD | -340.99% |
| 2006 Q1 | -318 Thousand USD | 97.16% |
| 2006 FY | -3.43 Million USD | 77.12% |
| 2005 FY | -14.99 Million USD | 56.38% |
| 2005 Q2 | -998 Thousand USD | 65.49% |
| 2005 Q3 | 111 Thousand USD | 111.12% |
| 2005 Q4 | -11.21 Million USD | -10202.7% |
| 2005 Q1 | -2.89 Million USD | 58.32% |
| 2004 Q2 | -15.13 Million USD | -292.12% |
| 2004 Q3 | -8.44 Million USD | 44.21% |
| 2004 Q4 | -6.93 Million USD | 17.82% |
| 2004 FY | -34.37 Million USD | -49.72% |
| 2004 Q1 | -3.85 Million USD | 55.1% |
| 2003 Q2 | -4.67 Million USD | -29.87% |
| 2003 Q3 | -6.09 Million USD | -30.56% |
| 2003 Q4 | -8.59 Million USD | -40.95% |
| 2003 Q1 | -3.59 Million USD | 61.4% |
| 2003 FY | -22.95 Million USD | -7.46% |
| 2002 Q2 | -3.98 Million USD | -18.52% |
| 2002 Q4 | -9.31 Million USD | -97.08% |
| 2002 Q1 | -3.35 Million USD | -23.67% |
| 2002 FY | -21.36 Million USD | -188.68% |
| 2002 Q3 | -4.72 Million USD | -18.74% |
| 2001 Q4 | -2.71 Million USD | -42.2% |
| 2001 FY | -7.4 Million USD | 14.55% |
| 2001 Q1 | -1.12 Million USD | -203.07% |
| 2001 Q2 | -1.64 Million USD | -46.1% |
| 2001 Q3 | -1.91 Million USD | -15.9% |
| 2000 FY | -8.66 Million USD | 11.86% |
| 2000 Q1 | -3.49 Million USD | 0.0% |
| 2000 Q2 | -2.71 Million USD | 22.43% |
| 2000 Q3 | -2.07 Million USD | 23.44% |
| 2000 Q4 | -372.18 Thousand USD | 82.08% |
| 1999 FY | -9.82 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 97.483% |
| Prenetics Global Limited | -62.72 Million USD | 90.669% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -278.101% |
| CareDx, Inc | -190.28 Million USD | 96.924% |
| Exact Sciences Corporation | -204.14 Million USD | 97.133% |
| Exagen Inc. | -23.68 Million USD | 75.292% |
| Inotiv, Inc. | -105.14 Million USD | 94.433% |
| Guardant Health, Inc. | -479.44 Million USD | 98.779% |
| Biodesix, Inc. | -52.14 Million USD | 88.776% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -122.629% |
| iSpecimen Inc. | -11.09 Million USD | 47.268% |
| Natera, Inc. | -434.8 Million USD | 98.654% |
| Aspira Women's Health Inc. | -16.69 Million USD | 64.931% |
| Standard BioTools Inc. | -74.65 Million USD | 92.16% |
| 23andMe Holding Co. | -666.7 Million USD | 99.122% |
| Castle Biosciences, Inc. | -57.46 Million USD | 89.815% |
| Personalis, Inc. | -108.29 Million USD | 94.595% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 93.385% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | 41.158% |
| OpGen, Inc. | -32.66 Million USD | 82.084% |
| T2 Biosystems, Inc. | -50.07 Million USD | 88.312% |
| Myriad Genetics, Inc. | -112 Million USD | 94.774% |
| ICON Public Limited Company | 612.33 Million USD | 100.956% |
| NeoGenomics, Inc. | -87.96 Million USD | 93.346% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -278.101% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 100.693% |
| RadNet, Inc. | 3.04 Million USD | 292.28% |
| MDxHealth SA | -43.1 Million USD | 86.42% |
| Psychemedics Corporation | -4.15 Million USD | -40.9% |
| Illumina, Inc. | -1.16 Billion USD | 99.496% |
| Check-Cap Ltd. | -17.56 Million USD | 66.684% |
| Twist Bioscience Corporation | -208.72 Million USD | 97.196% |
| DarioHealth Corp. | -59.42 Million USD | 90.151% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 96.512% |
| Sera Prognostics, Inc. | -36.24 Million USD | 83.85% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | 41.821% |
| OPKO Health, Inc. | -188.86 Million USD | 96.901% |
| Medpace Holdings, Inc. | 282.81 Million USD | 102.07% |
| Neogen Corporation | -9.42 Million USD | 37.873% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | 42.373% |
| Prenetics Global Limited | -62.72 Million USD | 90.669% |
| Mainz Biomed B.V. | -26.29 Million USD | 77.742% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 26.257% |
| Trinity Biotech plc | -24.01 Million USD | 75.631% |
| Neuronetics, Inc. | -30.18 Million USD | 80.612% |
| Sotera Health Company | 51.37 Million USD | 111.392% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 26.257% |